Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2016 Financial Results
March 16 2017 - 8:30AM
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage
biopharmaceutical company focused on discovering and developing
novel small molecule drug candidates to treat cancer, today
announced that Company management will release its year end 2016
financial results pre-market on March 27, 2017. The Company will
host a conference call at 9:00 a.m. Eastern Time on the same day.
Interested parties may access the call by dialing toll-free
(855) 428-5741 from the US, or (210) 229-8823 internationally and
using conference ID 79008554.
The call will also be webcast live at:
http://investor.onconova.com/events.cfm
A replay will be available at that link until June 30, 2017.
About Onconova Therapeutics, Inc.Onconova
Therapeutics, Inc. is a Phase 3 stage biopharmaceutical
company focused on discovering and developing novel small molecule
drug candidates to treat cancer, with a primary focus on
Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead
candidate, is a proprietary Phase 3 small molecule agent, which
blocks cellular signaling by targeting RAS effector pathways.
Using a proprietary chemistry platform, Onconova has created a
pipeline of targeted anti-cancer agents designed to work against
specific cellular pathways that are important in cancer cells,
while causing minimal damage to normal cells. Onconova
has three product candidates in clinical trials and several
active pre-clinical programs. Advanced clinical trials with
our lead compound, rigosertib, are aimed at unmet medical
needs of patients with MDS. For more information, please visit
http://www.onconova.com.
Forward Looking StatementsSome of the
statements in this release are forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
and involve risks and uncertainties. These statements relate to
future events or Onconova Therapeutics, Inc.'s future operations,
clinical development of Onconova's product candidates and
presentation of data with respect thereto, regulatory approvals,
expectations regarding the sufficiency of Onconova's cash and other
resources to fund operating expenses and capital expenditures,
Onconova's anticipated milestones and future expectations and plans
and prospects. Although Onconova believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Onconova has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "should," "approximately" or other words that
convey uncertainty of future events or outcomes. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors, including Onconova's need for
additional financing and current plans and future needs to scale
back operations if adequate financing is not obtained, the success
and timing of Onconova's clinical trials and regulatory approval of
protocols, and those discussed under the heading "Risk Factors" in
Onconova's most recent Annual Report on Form 10-K and quarterly
reports on Form 10-Q. Any forward-looking statements contained in
this release speak only as of its date. Onconova undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
GENERAL CONTACT:
http://www.onconova.com/contact/
INVESTOR RELATIONS CONTACT:
Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics
Lisa.Sher@mbsvalue.com / (212) 750-5800
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024